E Fund Management Co. Ltd. Increases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

E Fund Management Co. Ltd. increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 151.4% in the second quarter, HoldingsChannel.com reports. The fund owned 8,761 shares of the biotechnology company’s stock after acquiring an additional 5,276 shares during the period. E Fund Management Co. Ltd.’s holdings in Sarepta Therapeutics were worth $1,384,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in SRPT. Principal Securities Inc. bought a new position in Sarepta Therapeutics in the fourth quarter worth $26,000. Dimensional Fund Advisors LP increased its holdings in Sarepta Therapeutics by 10.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 224,201 shares of the biotechnology company’s stock worth $21,621,000 after buying an additional 20,923 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Sarepta Therapeutics by 125.3% in the 4th quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock worth $4,777,000 after buying an additional 27,549 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Sarepta Therapeutics by 65.2% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,108 shares of the biotechnology company’s stock worth $291,000 after buying an additional 1,227 shares in the last quarter. Finally, Norges Bank purchased a new position in Sarepta Therapeutics in the fourth quarter worth about $80,697,000. Institutional investors own 86.68% of the company’s stock.

Insiders Place Their Bets

In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the transaction, the insider now owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Sarepta Therapeutics news, EVP Ryan Edward Brown sold 38,957 shares of Sarepta Therapeutics stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the sale, the executive vice president now owns 17,129 shares in the company, valued at $2,768,217.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bilal Arif sold 7,859 shares of Sarepta Therapeutics stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now owns 21,261 shares in the company, valued at approximately $3,467,243.88. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 52,801 shares of company stock valued at $8,399,586. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $125.69 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The business’s 50 day moving average price is $139.24 and its 200-day moving average price is $132.69. The firm has a market capitalization of $11.88 billion, a PE ratio of 1,142.64 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.27) earnings per share. As a group, equities research analysts expect that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Leerink Partners lifted their price objective on Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. BMO Capital Markets boosted their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Evercore ISI upgraded Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and lowered their target price for the stock from $185.00 to $179.00 in a report on Thursday, August 8th. Piper Sandler dropped their price objective on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Finally, Robert W. Baird raised their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, June 21st. Three research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $187.39.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.